Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Chemother ; 36(1): 31-34, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-37602423

RESUMO

Bloodstream infections caused by vancomycin-resistant enterococci are increasingly reported and a consensus therapy does not exist. Oritavancin has shown good antimicrobial activity against VRE, but its use is mainly limited to skin, soft tissue, and/or bone infections. Fosfomycin is increasingly used for enterococcal infections (including bloodstream infections and endocarditis) as a partner drug given its anti-biofilm and synergistic properties. Recently in vitro and in vivo synergism between oritavancin and fosfomycin against VRE isolates has been demonstrated. Herein we report the case of a hematologic patient with a VRE bloodstream infection successfully treated with oritavancin and fosfomycin as sequential treatment.


Assuntos
Fosfomicina , Infecções por Bactérias Gram-Positivas , Lipoglicopeptídeos , Sepse , Enterococos Resistentes à Vancomicina , Humanos , Antibacterianos/uso terapêutico , Vancomicina/uso terapêutico , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Sepse/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA